<DOC>
	<DOCNO>NCT00474695</DOCNO>
	<brief_summary>The purpose study investigate whether efficacy Lucentis treatment exudative age-related macular degeneration associate VEGF HTRA1 DNA polymorphism</brief_summary>
	<brief_title>Study Evaluating Genotypes Using Lucentis</brief_title>
	<detailed_description>Treatment naive exudative AMD patient receive Lucentis treatment standard care , follow monthly 12 month . Standard ophthalmologic exam perform , along ETDRS visual acuity optical coherence tomography ( OCT ) . A blood sample obtain DNA analysis . The primary outcome measure change visual acuity 4 month initial Lucentis treatment . Secondary outcome change visual acuity retinal thickness 12 month .</detailed_description>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Treatment naive AMD patient ; At least 50 year age ; Visual acuity 20/40 20/320 Pregnancy ; Prior enrollment ranibizumab clinical trial ; Previous therapy either eye AMD ; Concurrent eye disease could compromise visual acuity</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Exudative age-related macular degeneration</keyword>
</DOC>